Andrew Toy, the Chief Executive Officer of Clover Health Investments, Corp., executed a mandatory stock sale on July 1, 2026, to satisfy tax withholding requirements tied to restricted stock unit vesting. The transaction involved the disposal of 313,476 shares of Class A Common Stock, resulting in proceeds of $1,667,692. Each share was sold at a price of $5.32.
This sale was not a discretionary trade by Mr. Toy. It was mandated by the issuer’s equity incentive plans, which require tax withholding obligations to be funded by a "sell to cover" transaction. The restricted stock units originally granted to Mr. Toy were issued on January 1, 2023.
Following this transaction, Mr. Toy directly holds 9,609,825 shares of Clover Health’s Class A Common Stock. The stock has since climbed to $5.40, trading near its 52-week high of $5.59, following a remarkable 96% gain over the past year. According to InvestingPro analysis, the stock currently appears overvalued relative to its Fair Value estimate, placing it among companies on the Most Overvalued list.
In other recent news, Clover Health Investments Corp reported its Q1 2026 earnings, showcasing a mixed financial performance. The company achieved revenue of $749.2 million, exceeding analyst expectations of $714.89 million. However, Clover Health’s earnings per share (EPS) came in at $0.05, falling short of the anticipated $0.07.
Additionally, the company’s Medicare star rating was upgraded to 4.5 stars from the previous 3.5 stars. This upgrade resulted from a court decision in Clover’s favor against the U.S. Department of Health and Human Services. The Centers for Medicare & Medicaid Services informed Clover of this recalibration following the court’s summary judgment.
These developments reflect significant changes for Clover Health in both its financial results and regulatory standing.